Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
Figure 1
Change in log10 viral load from baseline to Week 48 (nonvirologic failure censored) and virologic response by quartile ranges of (a) darunavir and (sparse pharmacokinetic sampling; ) and (b) etravirine and (sparse pharmacokinetic sampling;). In Figures 1(a) and 1(b), the numbers within the boxplots represent the median values, the boxes represent the 25th and 75th percentiles, and the whiskers represent the highest and lowest value within 1.5 interquartile range. : area under the plasma concentration–time curve over 12 hours; : trough concentration; DRV: darunavir; non-VF: nonvirologic failure censored population; ETR: etravirine.
